label int64 1 1 | id stringlengths 10 12 | original_id stringlengths 8 9 | text stringlengths 347 29.5k |
|---|---|---|---|
1 | 173067046_2 | 173067046 | months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rul... |
1 | 173067046_3 | 173067046 | company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any ne... |
1 | 173067046_b0 | 173067046 |
1,970
2021
1,970
2022
1,970
2023
1,970
Thereafter
16,085
Total minimum lease payments
25,926
Deferred rent related to lease incentives-non current 3,787
Deferred rent related to lease incentives-current 311
Aggregate rent expense
Rent expense
$ 1,667 $ 2,503 $ 2,871
Related party transaction (Details)... |
1 | 173067046_b1 | 173067046 | 2019
$ 4,670
2020
5,330
2021
5,425
2022
5,522
2023
5,620
Thereafter
40,977
Total minimum lease payments
67,544
Deferred rent related to lease incentives-non current 8,761
Deferred rent related to lease incentives-current 311
Aggregate rent expense
Rent expense
3,250
$ 3,606 $ 3,974
Lexington
Minimu... |
1 | 173068453_0 | 173068453 | Atlantica Yield Plc
Form 20-F
Filed on 28-Feb-2019 Period 31-Dec-2018 Accession number: 0001140361-19-004109
Included Items
1. 20-F 2. EX-4.14: EXHIBIT 4.14 3. EX-4.16: EXHIBIT 4.16 4. EX-4.17: EXHIBIT 4.17 5. EX-8.1: EXHIBIT 8.1 6. EX-12.1: EXHIBIT 12.1 7. EX-12.2: EXHIBIT 12.2 8. EX-13.1: EXHIBIT 13.1 9. EX-15.1: E... |
1 | 173068453_1 | 173068453 | (Mark One) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THESECURITIES EXCHANGEACT OF 1934
OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934
For the fiscal year ended December 31, 2018 OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT O... |
1 | 173068453_2 | 173068453 | of principal executive offices)
Santiago Seage Great West House, GW1, 17th floor
Great West Road Brentford, United Kingdom TW8 9DF
Tel: +44 203 499 0465
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the ... |
1 | 173068453_3 | 173068453 | report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the ... |
1 | 173068453_b0 | 173068453 | 845) (26,585)
Capital increase and other
0
0
0
C. Net cash provided by/(used in) financing activities
(77,289) (159,599) (26,585)
Net increase/(decrease) in cash and cash equivalents
(41,791) 26,371
76,667
Cash, cash equivalents and bank overdrafts at beginning of the year 148,525 122,154 45,487
Cash and cas... |
1 | 173068453_b1 | 173068453 | ,048) 40,664
81,956
Cash, cash equivalents and bank overdrafts at beginning of the year 669,387 594,811 514,712
Cash and cash equivalents at the end of the year
631,542 669,387 594,811
Parent Company [Member]
Condensed cash flowstatements [Abstract]
Cash Flow from operating activities
(30,571) 34,937
5,911
Ca... |
1 | 173069190_0 | 173069190 | Cushman & Wakefield Plc
Form 10-K
Filed on 28-Feb-2019 Period 31-Dec-2018 Accession number: 0001628369-19-000006
Included Items
1. 10-K 2. EX-10.36: EXHIBIT 10.36 3. EX-10.47: EXHIBIT 10.47 4. EX-10.48: EXHIBIT 10.48 5. EX-18.1: EXHIBIT 18.1 6. EX-21.1: EXHIBIT 21.1 7. EX-23.1: EXHIBIT 23.1 8. EX-31.1: EXHIBIT 31.1 9... |
1 | 173069190_1 | 173069190 | OF THESECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2018 or
TRANSITION REPORT PURSUANT TO SECTION 13 OR15(d) OF THESECURITIES EXCHANGEACT OF 1934
For the transition period from to. Commission File Number 001 - 38611
England and Wales
(State or other jurisdiction of incorporation or organizat... |
1 | 173069190_2 | 173069190 | as defined in Rule 405 of the Securities Act. Yes No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Secur... |
1 | 173069190_3 | 173069190 | Part III of this Form 10-K or any amendment to the Form 10-K. x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "sm... |
1 | 173069190_b0 | 173069190 | 0.09) $ (0.22) $ (0.23) $ (0.64) $ 0.14 $ (0.55) $ (0.33) $ (0.82)
Basic and diluted loss per common share attributable to shareholders (in dollars per share)
$ (1.09) $ (1.54) $ (3.07)
Adjustment
NewAccounting Pronouncements or Change in Accounting Principle [Line Items]
Total revenue
$ 0.0 $ 0.0 $ 0.0
Operatin... |
1 | 173069190_b1 | 173069190 | 052.7 1,709.3 1,700.6 1,461.3 8,219.9 6,923.9 6,215.7
Operating (loss)/income
43.2 20.6 30.6 (81.9) 37.2 (54.5) (35.6) (118.2) 12.6 (171.1) (295.4)
Net (loss) income
$ (18.0) $ (41.4) $ (33.5) $ (92.9) $ 22.2
$
(78.6)
$
(47.0)
$ (117.9)
$$$ (185.8) (221.3) (434.6)
Net (loss) earnings per share, basic (USD pe... |
1 | 173069439_0 | 173069439 | Talend SA
Form 10-K
Filed on 28-Feb-2019 Period 31-Dec-2018 Accession number: 0001668105-19-000005
Included Items
1. 10-K 2. EX-3.1 3. EX-10.19 4. EX-10.22 5. EX-21.1 6. EX-23.1 7. EX-31.1 8. EX-31.2 9. EX-32.1 10. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20... |
1 | 173069439_1 | 173069439 | specified in its charter)
France (State or other jurisdiction of incorporation or organization)
Not Applicable (I.R.S. employer identification no.)
9, rue Pages 92150 Suresnes, France (Address of principal executive offices)
+33 (0)1 46 25 06 00 (Registrant's telephone number, including area code)
Securities regi... |
1 | 173069439_2 | 173069439 | file reports pursuant to Section 13 or Section 15(d) ofthe Act. Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) ofthe Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required t... |
1 | 173069439_3 | 173069439 | a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of" large accelerated filer," " accelerated filer," and " emerging growth company" in Rule 12b-2 ofthe Exchange Act (Check one):
Large accelerated filer Non-accelerated... |
1 | 173069439_b0 | 173069439 |
$ 7
$ 139
Commitments and contingencies - Operating lease commitments (Details) -
USD ($) $ in Thousands
12 Months Ended Dec. 31, 2018 Dec. 31, 2017 Dec. 31, 2016
Operating lease commitments
Rent expenses on operating leases
$ 4,400 $ 3,400 $ 2,800
Future minimum undiscounted lease payments under operating lea... |
1 | 173069439_b1 | 173069439 | 1.68)
Net loss per share Antidilutive (Details) - shares
shares in Thousands
12 Months Ended Dec. 31, 2018 Dec. 31, 2017 Dec. 31, 2016
Stock Options
Net loss per share
Shares subject to outstanding ordinary share awards 1,707
2,282
2,828
Employee warrants (BSPCE)
Net loss per share
Shares subject to outstand... |
1 | 173070575_0 | 173070575 | NXP Semiconductors N.V.
Form 20-F
Filed on 01-Mar-2019 Period 31-Dec-2018 Accession number: 0001564590-19-005657
Included Items
1. 20-F 2. EX-4.13 3. EX-12.1 4. EX-12.2 5. EX-13.1 6. EX-13.2 7. EX-21.1 8. EX-23 9. XBRL (render)
As filed with the Securities and Exchange Commission on March 1, 2019
UNITED STATES SEC... |
1 | 173070575_1 | 173070575 | ACT OF 1934
OR
SHELLCOMPANYREPORT PURSUANT TO SECTION 13 OR15(d) OF THESECURITIES EXCHANGEACT OF 1934
Date of event requiring this shell company report
For the transition period from
to
Commission file number 001-34841
NXP Semiconductors N.V.
(Exact name of Registrant as specified in its charter)
The Netherlan... |
1 | 173070575_2 | 173070575 | ) 0.20 per share
The Nasdaq Global Select Market
Securities registered or to be registered pursuant to Section 12(g) of the Act.
None (Title of class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. Common shares--par value EUR 0.20 per share (Title of class)
Indicate the... |
1 | 173070575_3 | 173070575 | d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registran... |
1 | 173070575_b0 | 173070575 | , plant and equipment, net China [Member] Segment Reporting Information [Line Items] Revenue Property, plant and equipment, net Netherlands [Member] Segment Reporting Information [Line Items] Revenue Property, plant and equipment, net United States [Member] Segment Reporting Information [Line Items] Revenue Property, p... |
1 | 173070575_b1 | 173070575 | Member]
Goodwill [Line Items]
Translation differences and other changes
40
Corporate and Other [Member]
Goodwill [Line Items]
Beginning balance, Cost
270
[1]
Purchase price allocation to goodwill
0
[1]
Ending balance, Cost
270
[1]
Accumulated impairment at January 1, 2018
0
[1]
Accumulated impairment ... |
1 | 173071448_0 | 173071448 | ICON PLC
Form 20-F
Filed on 01-Mar-2019 Period 31-Dec-2018 Accession number: 0001060955-19-000004
Included Items
1. 20-F 2. EX-12.1: EXHIBIT 12.1 3. EX-12.2: EXHIBIT 12.2 4. EX-23.1: EXHIBIT 23.1 5. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.20549
________________________________... |
1 | 173071448_1 | 173071448 |
(Exact name of Registrant as Specified in its Charter)
ICON PUBLIC LIMITED COMPANY
(Translation of Registrant's name into English)
Ireland (Jurisdiction of Incorporation or Organization)
SOUTH COUNTY BUSINESS PARK, LEO PARDS TO WN, DUBLIN 18, IRELAND
(Address of principal executive offices)
Brendan Brennan, Chief F... |
1 | 173071448_2 | 173071448 | of the Act:
NONE
(Title of class)
Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: 53,971,706 Ordinary Shares.
Indicate by check mark if the registrant is a well-known seasoned issuer, as determined in R... |
1 | 173071448_3 | 173071448 | pursuant to Rule 405 of
Regulation S-T during the preceding 12 months: Yes X No__
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non- accelerated filer.
Large accelerated filer X
Accelerated filer __
Non-accelerated filer __ Emerging growth company _
If an ... |
1 | 173071448_b0 | 173071448 | OCI Attributable to Parent [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance
Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance
Common Stock [Member]
Common Stock, Shares, Issued
Stockholde... |
1 | 173071448_b1 | 173071448 | of investments in equity - long term Net cash used in investing activities Cash flows from financing activities: Financing costs Proceeds from the exercise of equity compensation Share issue costs Repurchase of ordinary shares Share repurchase costs Net cash used in financing activities Effect of exchange rate movemen... |
1 | 173072469_0 | 173072469 | Ardagh Group S.A.
Form 20-F
Filed on 01-Mar-2019 Period 31-Dec-2018 Accession number: 0001558370-19-001413
Included Items
1. 20-F 2. EX-1.1 3. EX-8.1 4. EX-12.1 5. EX-12.2 6. EX-13.1 7. EX-13.2 8. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGECOMMISSION Washington, D.C. 20549
FORM 20-F ANNUA... |
1 | 173072469_1 | 173072469 | L-2134 Luxembourg, Luxembourg
+352 26 25 85 55
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class Class A Common Shares, par value 0.01 per share
Name of each exchange on which registered New York Stock Exchange
Securities registered or to be registered pursuant to ... |
1 | 173072469_2 | 173072469 | has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filingrequirements for the past 90 days.
Yes No Indicate by check... |
1 | 173072469_3 | 173072469 |
Emerginggrowth company
U.S. GAAP
International Financial ReportingStandards as issued by the International AccountingStandards Board
Other
If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 __ It... |
1 | 173072469_b0 | 173072469 | ,158)
(1,509)
$ (1,359)
(1,374)
[2]
(2,179)
[2]
$ (2,155)
[2]
108
148
268
1,808
1,812
108 128 1,808
148 166 268 296
1,812
837
2,064
2,173 882
(191)
$ (222)
(94)
$ (103)
(335)
$ (370)
$ (3,573)
$
$
(3,547) (3,061)
(3,126)
(2,960)
(2,907)
[1] The consolidated income statements for the ... |
1 | 173072469_b1 | 173072469 | to cost | $ Consolidation Adjustments | Ardagh Group S.A. IFRS equity reconciliation: Additional loss if subsidiaries had been accounted for using the equity method of accounting as opposed to cost
12 Months Ended
Dec. Dec. Dec. Dec.
Dec.
Dec. Jan.
31, 31, 31, 31, Dec. 31, 31, Dec. 31, 31, 02, Dec. 31, Dec. 31, D... |
1 | 173073778_0 | 173073778 | Criteo S.A.
Form 10-K
Filed on 01-Mar-2019 Period 31-Dec-2018 Accession number: 0001576427-19-000014
Included Items
1. 10-K 2. EX-3.1: EXHIBIT 3.1 3. EX-4.3: EXHIBIT 4.3 4. EX-10.22: EXHIBIT 10.22 5. EX-21.1: EXHIBIT 21.1 6. EX-23.1: EXHIBIT 23.1 7. EX-31.1: EXHIBIT 31.1 8. EX-31.2: EXHIBIT 31.2 9. EX-32.1: EXHIBIT 3... |
1 | 173073778_1 | 173073778 |
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THESECURITIES EXCHANGEACT OF 1934
for the transition period from
to
Commission file number: 001-36153
Criteo S.A. (Exact name of registrant as specified in its charter)
France (State or other jurisdiction of incorporation
or organization)
Not Applicable (I.R... |
1 | 173073778_2 | 173073778 | the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the r... |
1 | 173073778_3 | 173073778 | information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions ... |
1 | 173073778_b0 | 173073778 | ]
Revenue
848,378 869,004 630,047
Germany
Segment Reporting Information [Line Items]
Revenue
203,020 183,297 137,116
United Kingdom
Segment Reporting Information [Line Items]
Revenue
97,849
115,226 115,053
Japan
Segment Reporting Information [Line Items]
Revenue
$ 351,441 $ 355,338 $ 285,959
Breakdown ... |
1 | 173073778_b1 | 173073778 |
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
954,073 990,424 730,873
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
839,825 808,961 660,523
Asia-Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue
506,416 497,307... |
1 | 173074084_0 | 173074084 | Medidata Solutions, Inc.
Form 10-K
Filed on 01-Mar-2019 Period 31-Dec-2018 Accession number: 0001453814-19-000061
Included Items
1. 10-K: FORM 10-K 2. EX-10.23: EXHIBIT 10.23 3. EX-21.1: SUBSIDIARIES OF MEDIDATA
SOLUTIONS, INC. 4. EX-23.1: CONSENT OF DELOITTE & TOUCHE
LLP 5. EX-31.1: CERTIFICATION OF CEO PURSUANT
TO ... |
1 | 173074084_1 | 173074084 | 14(B) OR 15D-14(B) 9. XBRL (render)
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________
FORM 10-K
_____________________________________
ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal ye... |
1 | 173074084_2 | 173074084 | 's telephone number, including area code)
Securities registered under Section 12(b) of the Exchange Act:
Title of each class
Name of each exchange on which registered
Common Stock, par value $0.01 per share
The NASDAQ Stock Market LLC
Securities registered under Section 12(g) of the Exchange Act: None
Indicate by... |
1 | 173074084_3 | 173074084 | everyInteractive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ý Yes ¨ No
Indicate bycheck mark if disclosure of delinquent fil... |
1 | 173074084_b0 | 173074084 | $
$
[1] $
[1]
167,187 163,406 155,905 149,198 141,589 138,945 136,027 127,644 635,696 544,205 458,493
124,058 121,179 118,404 112,896 108,884 107,391 104,107 97,030 476,537 417,412 345,884
11,035 14,119 12,837 13,326 17,359 22,257 12,661 12,879 51,317 65,156 48,686
$
14,319
$ 10,688
$ 16,589
$
10,325
$
17... |
1 | 173074084_b1 | 173074084 | Company's chief executive officer and
president would be two times such sum); (b) continuation of health benefits for one year (except that such
continuation for the Company's chief executive officer and president would be for two years); and (c) immediate
vesting of remaining unvested equity awards, unless otherwi... |
1 | 173079227_0 | 173079227 | Dova Pharmaceuticals Inc.
Form 10-K
Filed on 05-Mar-2019 Period 31-Dec-2018 Accession number: 0001685071-19-000008
Included Items
1. 10-K 2. EX-10.28: EXHIBIT 10.28 3. EX-10.29: EXHIBIT 10.29 4. EX-23.1: EXHIBIT 23.1 5. EX-23.2: EXHIBIT 23.2 6. EX-31.1: EXHIBIT 31.1 7. EX-31.2: EXHIBIT 31.2 8. EX-32.1: EXHIBIT 32.1 9... |
1 | 173079227_1 | 173079227 | 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from
to
.
Commission File Number 001- 38135
DOVA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
81-3858961
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identificatio... |
1 | 173079227_2 | 173079227 | check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for s... |
1 | 173079227_3 | 173079227 | ý
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rul... |
1 | 173079227_b0 | 173079227 |
0
5,533 4,847 4,508 3,416 $ 2,714
16,064 17,031 18,565 10,261 6,454
21,888 22,248 23,592 13,677 9,168 (19,046) (19,319) (19,008) (13,677) (9,168)
$ 5,426 4,185 9,611 (9,611)
$ 3,293 1,905 5,198 (5,198)
$ 4,276 955 5,231 (5,231)
1,180 0 18,304 15,710
61,921 13,499
81,405 29,209 (71,050) (29,209)
275
342
(195)... |
1 | 173079227_b1 | 173079227 |
Defined contribution plan, employer matching contribution, aggregate amount $ 248
$ 19
Maximum
Employee Benefit Plan
Employer matching contribution, as a percent of employee gross pay
4.00%
Selected Quarterly Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
Revenue: Revenue Operating expenses: Cost ... |
1 | 173081744_0 | 173081744 | ASTRAZENECA PLC
Form 20-F
Filed on 05-Mar-2019 Period 31-Dec-2018 Accession number: 0001104659-19-012881
Included Items
1. 20-F 2. EX-8.1 3. EX-12.1 4. EX-12.2 5. EX-13.1 6. EX-15.1 7. EX-15.2 8. EX-15.3 9. EX-15.4 10. EX-15.5 11. EX-15.6 12. EX-15.7 13. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSIO... |
1 | 173081744_1 | 173081744 | SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to.
OR
o SHELL COMPANYREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report...................
For the transition period from
to
.
Commission file n... |
1 | 173081744_2 | 173081744 | pursuant to Section 12(b) of the Act:
Title of each class
American Depositary Shares, each representing one half of an Ordinary Share of 25¢ each Ordinary Shares of 25¢ each 1.950% Notes due 2019 2.375% Notes due 2020 2.375% Notes due 2022 Floating Rate Notes due 2022 3.500% Notes due 2023 7.000% Notes due 2023 Float... |
1 | 173081744_3 | 173081744 | representing such Ordinary Shares pursuant to the requirements of the Securities and Exchange Commission. Securities registered or to be registered pursuant to Section 12(g) of the Act:
None (Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None (Title of Cl... |
1 | 173081744_b0 | 173081744 | OCI 0.05%
Biohaven Pharmaceutical Holding Company Ltd.
Significant and associate holdings Effective percentage of ownership interest in equity investment accounted for as FVOCI 0.25% BlinkBio Inc. Significant and associate holdings Effective percentage of ownership interest in equity investment accounted for as FVOC... |
1 | 173081744_b1 | 173081744 | OCI 0.69%
Silence Therapeutics PLC
Significant and associate holdings
Effective percentage of ownership interest in equity investment accounted for as FVOCI 0.17%
AbMed Corporation
Significant and associate holdings
Effective percentage of ownership interest in equity investment accounted for as FVOCI 18.00%
Aff... |
1 | 173088185_0 | 173088185 | Nucana Plc
Form 20-F
Filed on 07-Mar-2019 Period 31-Dec-2018 Accession number: 0001564590-19-006811
Included Items
1. 20-F 2. EX-12.1: EX-12.1 CEO CERTIFICATION 3. EX-12.2: EX-12.2 CFO CERTIFICATION 4. EX-13.1: EX-13.1 CEO CERTIFICATION 5. EX-13.2: EX-13.2 CFO CERTIFICATION 6. EX-15.1 7. XBRL (render)
As filed with... |
1 | 173088185_1 | 173088185 | 1934
For the fiscal year ended December 31, 2018
OR
TRANSITION REPORTPURSUANTTO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACTOF 1934
OR
SHELL COMPANY REPORTPURSUANTTO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACTOF 1934
Commission File Number 001-38215
NUCANA PLC
(Exact name of Registrant as specified... |
1 | 173088185_2 | 173088185 | 131 357 1111
info@nucana.com (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class American Depositary Shares, each representing one Ordinary Share, nominal value £0.04 per share
Name... |
1 | 173088185_3 | 173088185 | Exchange Act of 1934. Yes No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been s... |
1 | 173088185_b0 | 173088185 |
Percentage of increase in foreign exchange rate
1.00%
Reduction in financial assets and liabilities in foreign currencies £ (429,101) £ (747,004)
Financial Instruments Risk Management - Schedule of Financial Assets Subject to Fixed or Variable Interest Rates (Details) - GBP (£)
£ in Thousands
Dec. 31, 2018 Dec. 3... |
1 | 173088185_b1 | 173088185 | GBP (£)
£ in Thousands
Dec. 31, 2018 Dec. 31, 2017 Dec. 31, 2016 Dec. 31, 2015
Cash And Cash Equivalents [Abstract]
Cash and cash equivalents
£ 76,972 £ 86,703 £ 19,990 £ 14,112
Financial Instruments Risk Management - Additional Information (Details) - GBP
(£)
12 Months Ended Dec. 31, 2018 Dec. 31, 2017 Dec. 31... |
1 | 173089114_0 | 173089114 | Orion Engineered Carbons S.A.
Form 20-F
Filed on 08-Mar-2019 Period 31-Dec-2018 Accession number: 0001609804-19-000010
Included Items
1. 20-F: 20-F 2018 2. EX-8.1: EXHIBIT 8.1 3. EX-12.1: EXHIBIT 12.1 4. EX-12.2: EXHIBIT 12.2 5. EX-13.1: EXHIBIT 13.1 6. EX-13.2: EXHIBIT 13.2 7. EX-15.1: EXHIBIT 15.1 8. XBRL (render)
... |
1 | 173089114_1 | 173089114 | Securities Exchange Act of 1934 or
o Shell company report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001- 36563
ORION ENGINEERED CARBONS S.A.
(Exact Name of Registrant as Specified in its Charter)
N/A
(Translation of Registrant's Name into English)
Grand Duchy of L... |
1 | 173089114_2 | 173089114 | ) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstandingshares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report.
59,518,498 common shares, no par value
Ind... |
1 | 173089114_3 | 173089114 | to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) durin... |
1 | 173089114_b0 | 173089114 | 220,753
Long lived tangible assets
115,036 137,237
Brazil
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues
95,611
80,143
60,994
Long lived tangible assets
21,395
24,765
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues
75,638
64,645
45,318
... |
1 | 173089114_b1 | 173089114 | venues from External Customers and Long-Lived Assets [Line Items]
Long lived tangible assets
26,351
18,559
Italy
Revenues from External Customers and Long-Lived Assets [Line Items]
Long lived tangible assets
29,586
24,822
Poland
Revenues from External Customers and Long-Lived Assets [Line Items]
Long lived t... |
1 | 173094214_0 | 173094214 | Neon Therapeutics, Inc.
Form 10-K
Filed on 11-Mar-2019 Period 31-Dec-2018 Accession number: 0001694187-19-000026
Included Items
1. 10-K 2. EX-10.9: EXHIBIT 10.9 3. EX-10.10: EXHIBIT 10.10 4. EX-21.1: EXHIBIT 21.1 5. EX-23.1: EXHIBIT 23.1 6. EX-31.1: EXHIBIT 31.1 7. EX-31.2: EXHIBIT 31.2 8. EX-32.1: EXHIBIT 32.1 9. XB... |
1 | 173094214_1 | 173094214 | ESECURITIES EXCHANGEACT OF 1934
For the fiscal year ended December 31, 2018
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGEACT OF 1934
For the transition period from
to
Commission File Number 001-38551
________________________________________________________________
NEON THERAPEUTICS, ... |
1 | 173094214_2 | 173094214 | known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section ... |
1 | 173094214_3 | 173094214 | statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large a... |
1 | 173094214_b0 | 173094214 | (Unaudited) (Details) -
USD ($) $ / shares in Units, $ in
Thousands Quarterly Financial Information Disclosure [Abstract] Total operating expenses
Total other income (expense), net Net loss Accretion of redeemable convertible preferred stock to redemption value Net loss attributable to common stockholders
Net loss per... |
1 | 173094214_b1 | 173094214 | TRV | Accounts Payable and Accrued Liabilities
Related Parties
Accounts payable and accrued expenses due to related parties
$0 0
$ 0
Broad | License Agreement
Related Parties
Amount of expenses in relation to related party
2,000,000 800,000 $ 700,000
Accounts payable and accrued expenses due to related partie... |
1 | 173094751_0 | 173094751 | Cellectis S.A.
Form 20-F
Filed on 12-Mar-2019 Period 31-Dec-2018 Accession number: 0001193125-19-071189
Included Items
1. 20-F 2. EX-1.1 3. EX-4.1 4. EX-4.1.1 5. EX-4.1.2 6. EX-4.2 7. EX-4.2.1 8. EX-4.2.2 9. EX-4.2.3 10. EX-4.2.4 11. EX-4.3 12. EX-4.3.1 13. EX-4.7 14. EX-4.25 15. EX-4.26 16. EX-4.27 17. EX-4.28 18. E... |
1 | 173094751_1 | 173094751 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One)
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT
OF 1934
OR
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December ... |
1 | 173094751_2 | 173094751 | is S.A. 8, rue de la Croix Jarry
75013 Paris, France
(Address of principal executive office)
Marie-Bleuenn Terrier General Counsel Cellectis S.A.
8, rue de la Croix Jarry 75013 Paris, France
Tel: +33 (0)1 81 69 16 00, Fax: +33 (0)1 81 69 16 06
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Cont... |
1 | 173094751_3 | 173094751 |
Indicate the number of outstanding shares of each of the issuer's class of capital or common stock as of the close of the period covered by the annual report.
Ordinary shares, nominal value 0.05 per share: 42,430,069 as of December 31, 2018
Indicate by check mark if the registrant is a well-known seasoned issuer, as... |
1 | 173094751_b0 | 173094751 | Non-Employee Warrant One [member]
Disclosure of transactions between related parties [line items]
Number of non-employee warrants exercisable to obtain shares
220,175
Number of shares to be obtained upon exercise of warrants
50,000
Number of shares to be obtained upon exercise of warrants, strike price | / shar... |
1 | 173094751_b1 | 173094751 | is [member]
Disclosure of transactions between related parties [line items]
Purchase of common stock
550,000
Purchase of common stock
63,175
Purchase of common shares price per share | $ / shares
$ 19.49
Restricted Stock Units [member] | Calyxt Inc [member]
Disclosure of transactions between related parties [l... |
1 | 173094785_0 | 173094785 | LUXFER HOLDINGS PLC
Form 10-K
Filed on 12-Mar-2019 Period 31-Dec-2018 Accession number: 0001096056-19-000015
Included Items
1. 10-K 2. EX-3.1: EXHIBIT 3.1 3. EX-10.9: EXHIBIT 10.9 4. EX-10.10: EXHIBIT 10.10 5. EX-10.12: EXHIBIT 10.12 6. EX-10.13: EXHIBIT 10.13 7. EX-10.14: EXHIBIT 10.14 8. EX-10.15: EXHIBIT 10.15 9. ... |
1 | 173094785_1 | 173094785 | : EXHIBIT 31.1 16. EX-31.2: EXHIBIT 31.2 17. EX-32.1: EXHIBIT 32.1 18. EX-32.2: EXHIBIT 32.2 19. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,... |
1 | 173094785_2 | 173094785 | ) 161-300-0700 Securities registered pursuant to Section 12(b) of the Act:
Title of each class Ordinary Shares, nominal value £0.50 each
Name of each exchange on which registered New York Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if th... |
1 | 173094785_3 | 173094785 | chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the ... |
1 | 173094785_b0 | 173094785 | fer Holdings NA, LLC | Equity Method Investee
Related Party Transaction [Line Items]
Sales to related parties
600,000 5,000,000
Interest income from related party
400,000 300,000
Elektron | Nikkei-MEL Co. Limited | Equity Method Investee
Related Party Transaction [Line Items]
Sales to related parties
$ 900,000... |
1 | 173094785_b1 | 173094785 | ,000
Nikkei-MEL Co. Limited | Equity Method Investee
Related Party Transaction [Line Items]
Equity method investment, ownership percentage
50.00%
50.00%
Luxfer Holdings NA, LLC | Equity Method Investee
Related Party Transaction [Line Items]
Equity method investment, ownership percentage
49.00%
49.00%
Account... |
1 | 173095848_0 | 173095848 | PACIFIC DRILLING S.A.
Form 20-F
Filed on 12-Mar-2019 Period 31-Dec-2018 Accession number: 0001558370-19-001844
Included Items
1. 20-F 2. EX-1.1 3. EX-8.1 4. EX-12.1 5. EX-12.2 6. EX-13.1 7. EX-13.2 8. EX-15.1 9. EX-15.4 10. EX-15.5 11. XBRL (render)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. ... |
1 | 173095848_1 | 173095848 | THESECURITIESEXCHANGEACTOF1934
OR SHELLCOMPANYREPORTPURSUANTTOSECTION 13 OR 15 (d) OFTHESECURITIESEXCHANGEACTOF1934
Commission file number 001-35345
PACIFIC DRILLING S.A.
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant's name into English)
Luxembourg
(Jurisdiction of ... |
1 | 173095848_2 | 173095848 | NewYork Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) of the Act. None.
Securities for whichthere is a reporting obligationpursuant to Section15(d) of the Act. None.
Indicate the number ofoutstanding shares ofeach ofthe issuer's classes ofcapital or common stock as ofthe close o... |
1 | 173095848_3 | 173095848 | filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-Tduring the preceding 12 months (or for such shorter period that the registrant was required to submit ... |
1 | 173095848_b0 | 173095848 | ien PIK Notes
Related Party Transaction [Line Items]
Long-term debt face amount
$ 273.6
Predecessor | Second Lien PIK Notes
Related Party Transaction [Line Items]
Long-term debt face amount
$ 273.6
$ 273.6
QP
Related Party Transaction [Line Items]
Director fees paid
0.7
Related party legal fees
$ 3.2
QP ... |
1 | 173095848_b1 | 173095848 | ization Commitment fee Common Shares | Predecessor | Holders of Term Loan B, 2017 Notes and 2020 Notes Equity conversion (in shares) Issuance of common shares
Nov. 20, 2018
$ 1,152,443
Nov. 19, 2018
1 Months Ended
Sep. 26, Dec. 31, 2018 2018 $ 0 200
4,300
11 Months Ended
Nov. 19, 2018
12 Months Ended
Dec. 31, Dec.... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.